ShareSoc Growth Company Seminar (IN-PERSON EVENT), Leeds 8 October 2025 5pm
Featuring: N4 Pharma PLC (N4P), Built Cybernetics plc (BUC), Aptamer Group plc (APTA) and One Health Group plc (OHGR)
Location: Leonardo Hotel Leeds
Brewery Place, LS10 1NE
Companies presenting
N4 Pharma PLC (N4P)
N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.
RNA therapeutics are set to impact the treatment of a wide range of diseases, and Nuvec® has several key advantages for RNA gene delivery, including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.
N4 Pharma’s lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD), which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.
With an estimated 10 million people globally suffering from Crohn’s disease and ulcerative colitis, the IBD treatment market was worth $20.4bn in 2023 and is expected to grow by a CAGR of 3.9% to over $27.6bn by 2030, driven by both increased incidences of the disease and the development of new treatments.
For further information on the Company visit www.n4pharma.com or sign up at https://n4pharma.com/auth/signup
Presenter:
Nigel Theobald, CEO
Nigel has over 25 years’ experience in healthcare and in building businesses, strategy development and its implementation and a strong network covering all aspects of pharmaceutical product development and commercialisation. He was the head of healthcare brands at Boots Group plc in 2002 before leaving to set up a series of successful businesses, including Oxford Pharmascience Group plc, which he grew over 5 years into an AIM–quoted company with a market capitalisation of £40 million upon departure. Nigel formed N4 Pharma in 2014.
Built Cybernetics plc (BUC)
Built Cybernetics plc is an AIM-quoted PropTech group on a mission to revolutionise the built environment. Company’s new name reflects its vision. Built Cybernetics represents the evolution of the business—where AI, machine learning, and cybernetics shape the future of smart buildings. With a focus on design, delivery, and operation, the company pioneering intelligent buildings that enhance user experience while reducing financial and environmental costs. This shift builds on their success with AI-driven energy efficiency solutions and our continued expansion into PropTech innovation. For more information, please visit their website: https://builtcybernetics.com/s/4744b6
Presenters:
Nick Clark, CEO
Nick Clark is Chief Executive of Built Cybernetics plc (AUK:BUC), the PropTech group using AI to reshape the future of the built environment. The Group was formed when AIM-listed architecture firm Aukett Swanke Group plc acquired technology systems integrator Torpedo Factory Group. Three further acquisitions have followed.
Nick founded TFG in 1997 and has grown it through a combination of acquisitions and organic growth. Nick is also a non-executive director at Acuity RM Group plc, the AIM-quoted provider of cybersecurity risk management software.
Prior to starting TFG, Nick studied physics at Imperial College, followed by an MPhil in Microelectronic Engineering and Semiconductor Physics at the University of Cambridge.
Freddie Jenner, FCCA
Freddie Jenner was appointed Chief Operating Officer of Aukett Swanke Group Plc on 26 June 2023. He joined the group in March 2023 following the acquisition of Torpedo Factory Group, where he served as Chief Financial Officer since 2012. Freddie had joined that business in 2007 and worked with Nick to develop the business through a combination of acquisitions and organic growth.
Prior to joining TFG Freddie worked briefly in practice, following completion of a Mathematics and Actuarial Studies degree from the University of Southampton.
Aptamer Group plc (APTA)
Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.
Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.
Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.
For further information please visit https://aptamergroup.com
Presenter:
Dr Arron Tolley, Chief Executive Officer
Arron is the founder and Chief Executive Officer of Aptamer Group. Arron holds a Ph.D. in Molecular Biology and Biophysics from the University of Leeds and a B.Sc. in Molecular Medicine. Arron has over 20 years’ experience in the field of nucleic acid biology and has expertise in the development of aptamers against multiple target types, including complex cellular targets in model disease systems.
He led the growth of the company from a small laboratory built in the basement of his house to a successful aptamer development company. Arron has led the business through various stages of growth, and funding, including the AIM IPO in December 2021. Arron has extensive experience in business development, business administration and translational science and holds an honorary professorship for translational science and entrepreneurship from the University of Surrey.
One Health Group plc (OHGR)
One Health is quoted on AIM (OHGR), and is a profitable and growing business offering patients high-quality, clinical care services fully funded by the NHS. The business is strongly cash generative and pays a dividend.
One Health engages 80 NHS Consultants (excluding anaesthetists) who sub-specialise in the various surgeries offered by the Company, through a growing network of community-based outreach clinics and surgical operating locations. One Health continues to deliver strong growth and, in the year, to March 2025 provided much needed care to 17,020 new patients, through over 42,000 consultations and over 7,000 surgical procedures. One Health deploys surgeons and anaesthetists that are mostly employed by the NHS, on a subcontracted basis. It currently works with over 100 professionals across 9 independent hospitals and 37 outreach clinics. Within these community-based outreach clinics all consultations and post operative physiotherapy is delivered where required, reducing patient inconvenience and excess travel.
One Health’s activities are focused on areas where NHS patient needs are under-supplied by the local NHS service, population density is relatively high and the level of private medical insurance or the ability to self-fund is relatively low. Currently, the Company’s activities are focused in Yorkshire, Lincolnshire, Derbyshire, Nottinghamshire and Leicestershire. Revenue is derived from over 60 NHS commissioning bodies in addition to contracts with local NHS Hospital Trusts to transfer their internal waiting list patients to One Health for quicker treatment.
One Health’s business model has focused to date on four main areas: orthopaedics, spine, general surgery and gynaecology, with urology introduced at the end of FY25.
Spine and orthopaedics are particularly attractive areas for One Health as the Directors believe that they benefit from powerful growth drivers in terms of an ageing demographic, physical inactivity and an increasing proportion of the population being categorised as obese. Within orthopaedics, the most common surgeries performed by One Health are knee and hip replacements.
To sign up to receive information on One Health Group plc please email: onehealth@walbrookpr.com
Presenter:
Adam Binns, Chief Executive Officer
Adam joined One Health Group as Project Director & COO in January 2018, taking on the role of Finance Director & COO in May 2018 and Chief Executive in July 2019. Prior to joining One Health Adam worked extensively in senior financial, operational and commercial roles across retail, logistics and manufacturing. He takes great pride in recognising and developing talent and bringing out the best in his Senior Team and colleagues.
Adam is looking forward to developing One Health’s relationships with the NHS and providing first class care to a wider population of patients. He is a member of the Chartered Institute of Management Accountants.
This seminar consists of a 25-minute presentation by each company followed by 15 minutes of questions and answers. After the presentations there will be an hour of Networking with light buffet and wine where you will have the opportunity to engage directly with company directors and share your investing experience with fellow investors.
Event registration opens at 4.30 pm and presentations commence at 5.00 pm.
Places are limited and will be allocated on a first come, first served.
Stockopedia will provide facts and figures on the presenting companies for attendees (don’t forget that ShareSoc subscribing members can get a special discount on Stockopedia subscription rates – see Member Offers).
Registration
To register, members should log in, then just click “SUBMIT” below.
Click here for help on logging in or email events@sharesoc.org
If you are not yet a member, please complete the registration form below and you will automatically be granted Associate membership.
